Androgenetic Alopecia: Therapy Update

Ho CH, Sood T, Zito PM. Androgenetic alopecia. Treasure Island: StatPearls; 2022.

Google Scholar 

Price VH. Androgenetic alopecia in women. J Investig Dermatol Symp Proc. 2003;8(1):24–7.

Article  PubMed  Google Scholar 

Cranwell W, Sinclair R. Male androgenetic alopecia. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, et al., editors. Endotext. South Dartmouth; 2000.

Piraccini BM, Alessandrini A. Androgenetic alopecia. G Ital Dermatol Venereol. 2014;149(1):15–24.

CAS  PubMed  Google Scholar 

Osborn D. INHERITANCE OF BALDNESS various patterns due to heredity and sometimes present at birth—a sex-limited character—dominant in man—women not bald unless they inherit tendency from both parents. J Heredit. 1916;7:347–55.

McKusick VA. Alopecia, androgenetic, 1; AGA1: OMIM; 2008 [updated April 14, 2008]. https://omim.org/entry/109200#contributors. Accessed 10 Sept 2022.

Gordon KA, Tosti A. Alopecia: evaluation and treatment. Clin Cosmet Investig Dermatol. 2011;4:101–6.

Article  PubMed  PubMed Central  Google Scholar 

Phillips TG, Slomiany WP, Allison R. Hair loss: common causes and treatment. Am Fam Physician. 2017;96(6):371–8.

PubMed  Google Scholar 

Kasumagic-Halilovic E. Trichoscopic findings in androgenetic alopecia. Med Arch. 2021;75(2):109–11.

Article  PubMed  PubMed Central  Google Scholar 

Starace M, Orlando G, Alessandrini A, Piraccini BM. Female androgenetic alopecia: an update on diagnosis and management. Am J Clin Dermatol. 2020;21(1):69–84. https://doi.org/10.1007/s40257-019-00479-x. (PMID: 31677111).

Article  PubMed  Google Scholar 

Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. Br J Dermatol. 2004;150(2):186–94.

Article  CAS  PubMed  Google Scholar 

Olsen EA, Dunlap FE, Funicella T, Koperski JA, Swinehart JM, Tschen EH, Trancik RJ. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2002;47(3):377–85. https://doi.org/10.1067/mjd.2002.124088. (PMID: 12196747).

Article  PubMed  Google Scholar 

Gupta AK, Foley KA. 5% Minoxidil: treatment for female pattern hair loss. Skin Therapy Lett. 2014;19(6):5–7 (PMID: 25807073).

PubMed  Google Scholar 

McCoy J, Goren A, Kovacevic M, Shapiro J. Minoxidil dose response study in female pattern hair loss patients determined to be non-responders to 5% topical minoxidil. J Biol Regul Homeost Agents. 2016;30(4):1153–5.

CAS  PubMed  Google Scholar 

Blumeyer A, Tosti A, Messenger A, Reygagne P, Del Marmol V, Spuls PI, et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men. J Dtsch Dermatol Ges. 2011;9(Suppl 6):S1-57.

Article  PubMed  Google Scholar 

GoodRx. https://www.goodrx.com/. Accessed 10 Sept 2022.

Mazzarella GF, Loconsole GF, Cammisa GA, Mastrolonardo GM, Vena G. Topical finasteride in the treatment of androgenic alopecia. Preliminary evaluations after a 16-month therapy course. J Dermatolog Treat. 1997;8(3):189–92.

Article  Google Scholar 

Piraccini BM, Blume-Peytavi U, Scarci F, Jansat JM, Falques M, Otero R, et al. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. J Eur Acad Dermatol Venereol. 2022;36(2):286–94.

Article  CAS  PubMed  Google Scholar 

Rossi A, Magri F, D’Arino A, Pigliacelli F, Muscianese M, Leoncini P, et al. Efficacy of topical finasteride 0.5% vs 17alpha-estradiol 0.05% in the treatment of postmenopausal female pattern hair loss: a retrospective, single-blind study of 119 patients. Dermatol Pract Concept. 2020;10(2):e2020039.

Article  PubMed  PubMed Central  Google Scholar 

Valente Duarte d Sousa IC, Tosti A. New investigational drugs for androgenetic alopecia. Expert Opin Investig Drugs. 2013;22(5):573–89.

Article  Google Scholar 

Garza LA, Liu Y, Yang Z, Alagesan B, Lawson JA, Norberg SM, et al. Prostaglandin D2 inhibits hair growth and is elevated in bald scalp of men with androgenetic alopecia. Sci Transl Med. 2012;4(126):126ra34.

Article  PubMed  PubMed Central  Google Scholar 

Blume-Peytavi U, Lonnfors S, Hillmann K, Garcia BN. A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia. J Am Acad Dermatol. 2012;66(5):794–800.

Article  CAS  PubMed  Google Scholar 

Dhurat R, Sharma A, Rudnicka L, Kroumpouzos G, Kassir M, Galadari H, et al. 5-Alpha reductase inhibitors in androgenetic alopecia: shifting paradigms, current concepts, comparative efficacy, and safety. Dermatol Ther. 2020;33(3): e13379.

Article  CAS  PubMed  Google Scholar 

Iamsumang W, Leerunyakul K, Suchonwanit P. Finasteride and its potential for the treatment of female pattern hair loss: evidence to date. Drug Des Devel Ther. 2020;14:951–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rossi A, Cantisani C, Scarno M, Trucchia A, Fortuna MC, Calvieri S. Finasteride, 1 mg daily administration on male androgenetic alopecia in different age groups: 10-year follow-up. Dermatol Ther. 2011;24(4):455–61.

Article  CAS  PubMed  Google Scholar 

Kaufman KD, Rotonda J, Shah AK, Meehan AG. Long-term treatment with finasteride 1 mg decreases the likelihood of developing further visible hair loss in men with androgenetic alopecia (male pattern hair loss). Eur J Dermatol. 2008;18(4):400–6.

CAS  PubMed  Google Scholar 

Mysore V, Shashikumar BM. Guidelines on the use of finasteride in androgenetic alopecia. Indian J Dermatol Venereol Leprol. 2016;82(2):128–34.

Article  PubMed  Google Scholar 

Arca E, Açikgöz G, Taştan HB, Köse O, Kurumlu Z. An open, randomized, comparative study of oral finasteride and 5% topical minoxidil in male androgenetic alopecia. Dermatology. 2004;209(2):117–25. https://doi.org/10.1159/000079595. (PMID: 15316165).

Article  CAS  PubMed  Google Scholar 

Irwig MS. Depressive symptoms and suicidal thoughts among former users of finasteride with persistent sexual side effects. J Clin Psychiatry. 2012;73(9):1220–3.

Article  CAS  PubMed  Google Scholar 

Irwig MS, Kolukula S. Persistent sexual side effects of finasteride for male pattern hair loss. J Sex Med. 2011;8(6):1747–53.

Article  PubMed  Google Scholar 

Lynn R, Krunic A. Therapeutic hotline. Treatment of androgenic alopecia with finasteride may result in a high grade prostate cancer in patients: fact or fiction? Dermatol Ther. 2010;23(5):544–6.

Article  PubMed  Google Scholar 

Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab. 2004;89(5):2179–84.

Article  CAS  PubMed  Google Scholar 

Eun HC, Kwon OS, Yeon JH, Shin HS, Kim BY, Ro BI, et al. Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study. J Am Acad Dermatol. 2010;63(2):252–8.

Article  CAS  PubMed  Google Scholar 

Olsen EA, Hordinsky M, Whiting D, Stough D, Hobbs S, Ellis ML, et al. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol. 2006;55(6):1014–23.

Article  PubMed  Google Scholar 

Gupta AK, Venkataraman M, Talukder M, Bamimore MA. Relative efficacy of minoxidil and the 5-alpha reductase inhibitors in androgenetic alopecia treatment of male patients: a network meta-analysis. JAMA Dermatol. 2022;158(3):266–74.

Article  PubMed  PubMed Central  Google Scholar 

Herz-Ruelas ME, Alvarez-Villalobos NA, Millan-Alanis JM, de Leon-Gutierrez H, Ocampo-Garza SS, Gomez-Flores M, et al. Efficacy of intralesional and oral dutasteride in the treatment of androgenetic alopecia: a systematic review. Skin Appendage Disord. 2020;6(6):338–45.

Article  PubMed  PubMed Central  Google Scholar 

Sinclair RD. Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. Int J Dermatol. 2018;57(1):104–9.

Article  CAS  PubMed  Google Scholar 

Panchaprateep R, Lueangarun S. Efficacy and safety of oral minoxidil 5 mg once daily in the treatment of male patients with androgenetic alopecia: an open-label and global photographic assessment. Dermatol Ther (Heidelb). 2020;10(6):1345–57. https://doi.org/10.1007/s13555-020-00448-x. (Epub 2020 Sep 24. PMID: 32970299; PMCID: PMC7649170).

Article  PubMed  PubMed Central  Google Scholar 

Vastarella M, Cantelli M, Patri A, Annunziata MC, Nappa P, Fabbrocini G. Efficacy and safety of oral minoxidil in female androgenetic alopecia. Dermatol Ther. 2020;33(6): e14234.

Article  CAS  PubMed  Google Scholar 

Ramos PM, Sinclair RD, Kasprzak M, Miot HA. Minoxidil 1 mg oral versus minoxidil 5% topical solution for the treatment of female-pattern hair loss: a randomized clinical trial. J Am Acad Dermatol. 2020;82(1):252–3.

Article  PubMed  Google Scholar 

Randolph M, Tosti A. Oral minoxidil treatment for hair loss: a review of efficacy and safety. J Am Acad Dermatol. 2021;84(3):737–46.

Article  CAS  PubMed  Google Scholar 

Xing L, Dai Z, Jabbari A, Cerise JE, Higgins CA, Gong W, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014;20(9):1043–9.

Article 

留言 (0)

沒有登入
gif